Skip to content
The Nexus
DossierENTITY

Semavy

Coverage of Semavy in the Nexus archive.

Earliest in view: Jun 25 · 08:17 UTCMost recent: Jun 25 · 08:17 UTC
Co-mentioned in this coverage
Hyperaorganization1Novo Nordiskorganization1Ozempicproduct1EMSorganization1semaglutidetopic1Brazilplace1weight-loss markettopic1
Recent coverage
  • BUSINESSJun 25 · 08:17 UTCTHE RIO TIMES
    A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market

    Brazil's Hypera filed to launch Semavy, a semaglutide pen targeting the same drug class as Novo Nordisk's Ozempic. The Brazilian semaglutide market generates at least R$5bn ($960m) annually, and the drug's patent expired in March 2026. Rival EMS already secured approval for a competing product.